newsfilter

$COV News

Last published 6y ago

  • 6y agoMDWELLWPGSPG+11MEDNAX Announces Leadership and Board TransitionsBusiness WireFORT LAUDERDALE, Fla.--(BUSINESS WIRE)--MEDNAX, Inc. (NYSE: MD), the nation’s leading provider of maternal-fetal, newborn and pediatric subspecialty care, today announced that the Company’s Board of Directors has appointed Mark S. Ordan as Chief Executive Officer, succeeding Roger J. Medel, M.D., the Company’s founder. Dr. Medel will remain a member of the Board until the 2021 Annual Meeting of Sh ...
  • 10y agoHRCMASICOVAutomated Vital Signs Solutions from Welch Allyn Help Ensure Accurate Readings, Enable Early Detection in the Battle to Curb Hypertension across CanadaBusiness WireMISSISSAUGA, Ontario--(BUSINESS WIRE)--Welch Allyn, a leading medical diagnostic device company that is a division of Hill-Rom (NYSE:HRC), recently introduced three new automated vital signs solutions that can help healthcare providers across Canada capture vitals accurately and efficiently, and detect hypertension early in ambulatory care settings.
  • 11y agoCOVCovidien Announces Effectiveness of Medtronic Transaction Scheme of ArrangementBusiness WireDUBLIN, Ireland--(BUSINESS WIRE)--Covidien plc (NYSE: COV) today announced, for purposes of the Irish Takeover Rules, that the scheme of arrangement under which Medtronic acquired Covidien under a new holding company incorporated in Ireland to be named Medtronic plc has become effective.
  • 11y agoCOVCovidien Supports Retreat & Refresh Stroke Camp for Stroke Survivors and CaregiversBusiness WireDUBLIN, Ireland--(BUSINESS WIRE)--Covidien is sponsoring the Retreat & Refresh Stroke Camp (Stroke Camp), a three-day retreat for stroke survivors, caregivers and family members dedicated to helping these often forgotten victims of stroke relax and heal. Stroke Camp will be held Jan. 23-25, 2015 in La Jolla, California, and is offered to 15 couples with support from the University of California, S ...
  • 11y agoCOVCovidien Reports First-Quarter 2015 ResultsBusiness WireDUBLIN, Ireland--(BUSINESS WIRE)--Covidien plc (NYSE: COV) today announced financial results for the first quarter of fiscal 2015. First-quarter net sales of $2.69 billion increased 2% from the $2.64 billion in the first quarter a year ago. Operational sales growth in the quarter was 6%, as foreign exchange rate movement lowered the quarterly sales growth rate by four percentage points.
  • 11y agoCOVAnnouncement under Irish Takeover Rules Relevant Securities in Issue – January 21, 2015Business WireDUBLIN, Ireland--(BUSINESS WIRE)--In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc (NYSE: COV) (the “Company”) confirms that, as of the close of business on January 20, 2015, the Company’s issued share capital, excluding treasury shares, consisted of 454,507,245 ordinary shares, par value US$0.20 per share (the “Ordinary Shares”). The International Securities Identification N ...
  • 11y agoCOVCovidien plc to Report First-Quarter Fiscal 2015 Results on January 22, 2015Business WireDUBLIN, Ireland--(BUSINESS WIRE)--Covidien plc (NYSE: COV) will report first-quarter fiscal 2015 results on January 22. Results will be filed via Form 8K and available prior to market open at www.covidien.com/investor. The company will not be hosting a conference call.
  • 11y agoCOVAnnouncement under Irish Takeover Rules Relevant Securities in Issue – January 14, 2015Business WireDUBLIN, Ireland--(BUSINESS WIRE)--In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc (NYSE: COV) (the “Company”) confirms that, as of the close of business on January 13, 2015, the Company’s issued share capital, excluding treasury shares, consisted of 454,294,351 ordinary shares, par value US$0.20 per share (the “Ordinary Shares”). The International Securities Identification N ...
  • 11y agoCOVCovidien’s Stellarex™ Drug-Coated Angioplasty Balloon Receives CE Mark to Treat Peripheral Arterial Disease PatientsBusiness WireDUBLIN, Ireland--(BUSINESS WIRE)--Covidien plc (NYSE:COV) today announced it has received CE Mark approval for its Stellarex™ drug-coated angioplasty balloon (DCB). The Stellarex™ DCB is used to restore and maintain blood flow to the arteries of the leg in patients with peripheral arterial disease (PAD).
  • 11y agoCOVAnnouncement under Irish Takeover Rules Relevant Securities in Issue – January 8, 2015Business WireDUBLIN, Ireland--(BUSINESS WIRE)--In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc (NYSE: COV) (the “Company”) confirms that, as of the close of business on January 7, 2015, the Company’s issued share capital, excluding treasury shares, consisted of 454,109,105 ordinary shares, par value US$0.20 per share (the “Ordinary Shares”). The International Securities Identification Nu ...
  • 11y agoCOVAnnouncement under Irish Takeover Rules -- Results of Covidien plc's Shareholder MeetingsBusiness WireDUBLIN, Ireland--(BUSINESS WIRE)--On January 6, 2015, Covidien plc, a public limited company organized under the laws of Ireland, held a special court-ordered meeting of shareholders and an extraordinary general meeting of shareholders, in each case relating to the pending acquisition of Covidien by Medtronic, Inc., through Medtronic Holdings Limited, a new holding company incorporated in Ireland ...
  • 11y agoCOVAnnouncement under Irish Takeover Rules Relevant Securities in Issue – December 30, 2014Business WireDUBLIN, Ireland--(BUSINESS WIRE)--In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc (NYSE: COV) (the “Company”) confirms that, as of the close of business on December 29, 2014, the Company’s issued share capital, excluding treasury shares, consisted of 454,006,720 ordinary shares, par value US$0.20 per share (the “Ordinary Shares”). The International Securities Identification ...
  • 11y agoCOVAnnouncement under Irish Takeover Rules Relevant Securities in Issue – December 23, 2014Business WireDUBLIN, Ireland--(BUSINESS WIRE)--In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc (NYSE: COV) (the “Company”) confirms that, as of the close of business on December 22, 2014, the Company’s issued share capital, excluding treasury shares, consisted of 453,883,765 ordinary shares, par value US$0.20 per share (the “Ordinary Shares”). The International Securities Identification ...
  • 11y agoCOVCovidien Declares Quarterly Cash DividendBusiness WireDUBLIN, Ireland--(BUSINESS WIRE)--Covidien plc (NYSE: COV) today announced that its Board of Directors has declared a quarterly cash dividend of $0.36 per ordinary share. The quarterly dividend is payable on Jan. 16, 2015, to shareholders of record on Jan. 2, 2015.
  • 11y agoCOVNew Study Shows Addition of Stent Thrombectomy More Effective Than Traditional Pharmaceutical Treatment for Acute Ischemic Stroke PatientsBusiness WireDUBLIN, Ireland--(BUSINESS WIRE)--In a landmark study evaluating the addition of stent thrombectomy clot removal to pharmaceutical treatment for patients suffering an acute ischemic stroke (AIS), stent thrombectomy provided a significant clinical benefit when compared to pharmaceutical treatment alone. Results from the Multi center Randomized Clinical trial of Endovascular treatment for Acute isch ...
  • 11y agoCOVCovidien’s Unique Capsule Endoscopy PillCam® SB Featured in New Smithsonian Exhibit ‘Tools: Extending Our Reach’Business WireNEW YORK--(BUSINESS WIRE)--PillCam® SB, Covidien’s wireless capsule endoscope, is now featured in the exhibit, “Tools: Extending Our Reach” at New York’s Cooper Hewitt Smithsonian Design Museum. PillCam SB is one of 175 installations highlighting how tools and innovations have extended the capabilities of the human body over the past two million years. The museum reopened on Dec. 12 after a three ...
  • 11y agoCOVAnnouncement under Irish Takeover Rules Relevant Securities in Issue – December 11, 2014Business WireDUBLIN, Ireland--(BUSINESS WIRE)--In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc (NYSE: COV) (the “Company”) confirms that, as of the close of business on December 10, 2014, the Company’s issued share capital, excluding treasury shares, consisted of 453,773,707 ordinary shares, par value US$0.20 per share (the “Ordinary Shares”). The International Securities Identification ...
  • 11y agoCOVAnnouncement under Irish Takeover Rules Relevant Securities in Issue – December 9, 2014Business WireDUBLIN, Ireland--(BUSINESS WIRE)--In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc (NYSE: COV) (the “Company”) confirms that, as of the close of business on December 8, 2014, the Company’s issued share capital, excluding treasury shares, consisted of 453,612,034 ordinary shares, par value US$0.20 per share (the “Ordinary Shares”). The International Securities Identification N ...
  • 11y agoCOVForm 8.1 – CovidienBusiness WireDUBLIN, Ireland--(BUSINESS WIRE)--Covidien plc:
  • 11y agoCOVForm 8.1 - CovidienBusiness WireDUBLIN, Ireland--(BUSINESS WIRE)--FORM 8.1(a)&(b)(i)
  • 11y agoCOVForm 8.1 - CovidienBusiness WireDUBLIN, Ireland--(BUSINESS WIRE)--Covidien plc:
  • 11y agoCOVForm 8.1 - CovidienBusiness WireDUBLIN, Ireland--(BUSINESS WIRE)--Covidien:
  • 11y agoCOVAnnouncement under Irish Takeover Rules Relevant Securities in Issue – December 5, 2014Business WireDUBLIN, Ireland--(BUSINESS WIRE)--In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc (NYSE: COV) (the “Company”) confirms that, as of the close of business on December 4, 2014, the Company’s issued share capital, excluding treasury shares, consisted of 453,450,240 ordinary shares, par value US$0.20 per share (the “Ordinary Shares”). The International Securities Identification N ...
  • 11y agoCOVAnnouncement under Irish Takeover Rules Relevant Securities in Issue – December 4, 2014Business WireDUBLIN, Ireland--(BUSINESS WIRE)--In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc (NYSE: COV) (the “Company”) confirms that, as of the close of business on December 3, 2014, the Company’s issued share capital, excluding treasury shares, consisted of 453,218,565 ordinary shares, par value US$0.20 per share (the “Ordinary Shares”). The International Securities Identification N ...
  • 11y agoCOVAnnouncement under Irish Takeover Rules Relevant Securities in Issue – December 3, 2014Business WireDUBLIN, Ireland--(BUSINESS WIRE)--In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc (NYSE: COV) (the “Company”) confirms that, as of the close of business on December 2, 2014, the Company’s issued share capital, excluding treasury shares, consisted of 453,075,299 ordinary shares, par value US$0.20 per share (the “Ordinary Shares”). The International Securities Identification N ...
  • 11y agoCOVAnnouncement under Irish Takeover Rules Relevant Securities in Issue – December 2, 2014Business WireDUBLIN, Ireland--(BUSINESS WIRE)--In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc (NYSE: COV) (the “Company”) confirms that, as of the close of business on December 1, 2014, the Company’s issued share capital, excluding treasury shares, consisted of 452,832,461 ordinary shares, par value US$0.20 per share (the “Ordinary Shares”). The International Securities Identification N ...
  • 11y agoCOVCovidien’s Fortrex™ PTA Balloon Receives FDA 510(k) ClearanceBusiness WireDUBLIN, Ireland--(BUSINESS WIRE)--Covidien plc (NYSE: COV) today announced U.S. Food and Drug Administration 510(k) clearance for its Fortrex™ over-the-wire (OTW) percutaneous transluminal angioplasty (PTA) balloon catheter. The Fortrex™ 0.035” OTW PTA balloon catheter —the next-generation high pressure solution to maintain arteriovenous (AV) access—is also intended for use in the peripheral vascu ...
  • 11y agoCOVCovidien Announces Mailing of Definitive Joint Proxy Statement/ProspectusBusiness WireDUBLIN, Ireland--(BUSINESS WIRE)--Covidien plc (NYSE: COV) today announced, for purposes of the Irish Takeover Rules, that the definitive joint proxy statement of Covidien plc and Medtronic, Inc., which also serves as a prospectus of Medtronic Holdings Limited and comprises Covidien’s scheme circular required under Irish law is being sent today to Covidien and Medtronic, Inc., shareholders.
  • 11y agoCOVCovidien Achieves CE Mark for the Nellcor™ Bedside SpO2 Patient Monitoring System, PM100NBusiness WireDUBLIN, Ireland--(BUSINESS WIRE)--Covidien (NYSE: COV) today announced CE Mark approval for its Nellcor™ Bedside SpO2 Patient Monitoring System, PM100N. The system currently is available in the European Economic Area (EEA), Australia and New Zealand. The Nellcor™ Bedside SpO2 Patient Monitoring System is the only commercially available bedside pulse oximetry (SpO2) monitor featuring home care and ...
  • 11y agoCOVAnnouncement under Irish Takeover Rules Relevant Securities in Issue – November 19, 2014Business WireDUBLIN, Ireland--(BUSINESS WIRE)--In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc (NYSE: COV) (the “Company”) confirms that, as of the close of business on November 18, 2014, the Company’s issued share capital, excluding treasury shares, consisted of 452,731,347 ordinary shares, par value US$0.20 per share (the “Ordinary Shares”). The International Securities Identification ...
  • 11y agoMDTCOVMedtronic and Covidien Shareholder Meetings Scheduled for January 6, 2015Business WireMINNEAPOLIS & DUBLIN, Ireland--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) and Covidien plc (NYSE: COV) announced that following a hearing today before the Irish High Court the companies have scheduled shareholder meetings for Tuesday, January 6, 2015, in connection with the pending acquisition of Covidien by Medtronic.
  • 12y agoCOVSix Month Results of VeClose Study Demonstrate Safety, Effectiveness of the VenaSealTM Closure SystemBusiness WireDUBLIN, Ireland--(BUSINESS WIRE)--Covidien plc (NYSE:COV) today announced the six-month results of the VeClose pivotal study, which demonstrated the safety and effectiveness of the VenaSeal™ closure system* in patients with chronic venous insufficiency (CVI) having symptomatic reflux in the great saphenous vein. The results were presented at American College of Phlebology Annual Congress (ACP 2014 ...
  • 12y agoCOVForm 8.1 – CovidienBusiness WireDUBLIN, Ireland--(BUSINESS WIRE)--Covidien plc:
  • 12y agoCOVCovidien Announces Nine-Month Results of DURABILITY Iliac Study, Addition of Iliac Indication for EverFlex™ Stent System at VIVA 2014Business WireLAS VEGAS--(BUSINESS WIRE)--Covidien plc (NYSE: COV) today announced nine-month results of the DURABILITY Iliac study and addition of the iliac indication for its EverFlex™ stent at the Vascular Interventional Advances (VIVA) 2014 conference. The nine-month results confirm the safety and effectiveness of the EverFlex™ and Protégé™ GPS™ self-expanding stent systems* for the treatment of lesions of ...
  • 12y agoCOVCovidien Reports Fourth-Quarter and Fiscal 2014 ResultsBusiness WireDUBLIN, Ireland--(BUSINESS WIRE)--Covidien plc (NYSE: COV) today announced financial results for the fourth quarter of fiscal 2014. Fourth-quarter net sales of $2.73 billion increased 7%, both on a reported and on an operational basis, from the $2.56 billion in the fourth quarter a year ago.
  • 12y agoCOVCovidien Announces 12-Month DEFINITIVE AR Results at VIVA 2014Business WireLAS VEGAS--(BUSINESS WIRE)--Covidien plc (NYSE: COV) today announced 12-month results of the DEFINITIVE AR study, the first randomized study designed to identify the clinical benefits of plaque removal using directional atherectomy followed by drug coated balloon. The results were presented by Professor Thomas Zeller of the Universitaets-Herzzentrum, Bad Krozingen, Germany at the Vascular Interven ...
  • 12y agoCOVCovidien’s HawkOne™ Directional Atherectomy System Receives FDA 510(K) Clearance for the Treatment of Peripheral Arterial DiseaseBusiness WireDUBLIN, Ireland--(BUSINESS WIRE)--Covidien plc (NYSE: COV) today announced U.S. Food and Drug Administration 510(k) clearance for the HawkOne™ directional atherectomy system. The latest addition to Covidien’s directional atherectomy portfolio, the HawkOne™ system provides physicians with an enhanced cutting mechanism to more effectively treat the widest variety of plaque in patients with periphera ...
  • 12y agoCOVCovidien Launches First and Only Articulating Reloadable Absorbable Fixation Device for Minimally-Invasive Hernia RepairBusiness WireDUBLIN, Ireland--(BUSINESS WIRE)--Covidien plc (NYSE:COV) today announced the launch of ReliaTack™ articulating reloadable fixation device, the first and only of its kind for laparoscopic (minimally invasive) hernia repair.‡
  • 12y agoCOVCovidien Launches Next-Generation SuperDimension™ Lung Navigation Software to Simplify Planning, Enhance Visualization During a ProcedureBusiness WireDUBLIN--(BUSINESS WIRE)--Further underscoring its ongoing commitment to lung health, Covidien (NYSE:COV) today unveiled a next-generation version of its superDimension™ Navigation System software. The updated software features a more intuitive interface that helps reduce time spent by physicians planning the procedure and enhances the visualization of the airways of the lung.
  • 12y agoCOVCovidien Joins Forces with the American Lung Association to Help Women Understand Their Increased Risk of Lung CancerBusiness WireDUBLIN, Ireland--(BUSINESS WIRE)--Covidien (NYSE: COV) is joining forces with the American Lung Association’s LUNG FORCE movement to raise awareness of the threat that lung cancer poses to women. As Education Sponsor of LUNG FORCE, the company is working to promote greater understanding of lung cancer.
  • 12y agoCOV93% of U.S., 92% of New Yorkers Unaware that Stroke is Second Leading Cause of Death GloballyBusiness WireNEW YORK--(BUSINESS WIRE)--Despite its being the second leading cause of death worldwide, 93% of Americans still do not recognize the global threat stroke poses and the warning signs associated with it, according to a new public opinion study sponsored by Covidien and the World Stroke Organization (WSO).
  • 12y agoCOVU.S. District Court Grants Covidien Preliminary Injunction against Ethicon’s Harmonic ACE®+7Business WireDUBLIN, Ireland--(BUSINESS WIRE)--Covidien plc (NYSE: COV) today announced that the U.S. District Court for the District of Connecticut has granted a preliminary injunction against Ethicon Endo-Surgery, Inc., a Johnson & Johnson company. This injunction results from a lawsuit filed by Covidien in June 2014 that alleges Ethicon’s latest ultrasonic surgical product, the Harmonic ACE®+7, infringes th ...
  • 12y agoCOVAnnouncement under Irish Takeover Rules Relevant Securities in Issue – October 10, 2014Business WireDUBLIN, Ireland--(BUSINESS WIRE)--In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc (NYSE: COV) (the “Company”) confirms that, as of the close of business on October 9, 2014, the Company’s issued share capital, excluding treasury shares, consisted of 452,620,558 ordinary shares, par value US$0.20 per share (the “Ordinary Shares”). The International Securities Identification Nu ...
  • 12y agoCOVCovidien Announces U.S. Food and Drug Administration 510(k) Clearance for Nellcor™ Portable SpO2 Patient Monitoring SystemBusiness WireDUBLIN, Ireland--(BUSINESS WIRE)--Covidien plc (NYSE: COV) today announced U.S. Food and Drug Administration 510(k) clearance for the Nellcor™ Portable SpO2 Patient Monitoring System (PM10N). The system is the only commercially available portable oximeter that is equipped with home care and sleep study modes and complies with IEC 60601-1-11 standards for devices used in the home health care enviro ...
  • 12y agoCOVForm 8.1 – CovidienBusiness WireDUBLIN, Ireland--(BUSINESS WIRE)--Covidien plc:
  • 12y agoCOVForm 8.1 – CovidienBusiness WireDUBLIN, Ireland--(BUSINESS WIRE)--FORM 8.1(a)&(b)(i)
  • 12y agoCOVForm 8.1 – CovidienBusiness WireDUBLIN, Ireland--(BUSINESS WIRE)--FORM 8.1(a)&(b)(i)
  • 12y agoCOVAnnouncement under Irish Takeover Rules Relevant Securities in Issue – October 7, 2014Business WireDUBLIN, Ireland--(BUSINESS WIRE)--In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc (NYSE: COV) (the “Company”) confirms that, as of the close of business on October 6, 2014, the Company’s issued share capital, excluding treasury shares, consisted of 452,488,239 ordinary shares, par value US$0.20 per share (the “Ordinary Shares”). The International Securities Identification Nu ...
  • 12y agoCOVSurvey Shows 43 Percent of Americans Ages 40 and Older Have Experienced Symptoms of Peripheral Arterial Disease (PAD)Business WireDUBLIN, Ireland--(BUSINESS WIRE)--More than 40 percent of Americans aged 40 and older have experienced one or more of the most common symptomsi of peripheral arterial disease (PAD). However, the majority are unfamiliar with the disease and relatively few who experience symptoms see a doctor, according a recent online awareness survey conducted by Harris Poll.ii
  • 12y agoCOVCovidien plc to Report Fourth-Quarter and Fiscal 2014 Results on November 5, 2014Business WireDUBLIN, Ireland--(BUSINESS WIRE)--Covidien plc (NYSE: COV) will report fourth-quarter and fiscal 2014 results on November 5. The company will host a conference call for investors at 8:30 a.m. ET. The call can be accessed in the following ways: